Wegovy (Semaglutide) for Weight Loss: A Houston Patient Guide

Wegovy (semaglutide 2.4 mg) is FDA-approved for chronic weight management in adults with obesity (BMI ≥30) or overweight (BMI ≥27) with a weight-related health condition. It contains the same semaglutide molecule as Ozempic but at a higher maximum dose — 2.4 mg weekly vs. 1.0–2.0 mg for Ozempic. The higher dose produces significantly greater weight loss (average 15% vs 5–7%). The two medications also use different insurance pathways: Ozempic uses diabetes coverage, Wegovy uses obesity/weight management coverage.

In the landmark STEP-1 clinical trial, adults taking Wegovy 2.4 mg lost an average of 14.9% of body weight over 68 weeks — roughly 33 pounds for a 220-pound person. About 1 in 3 participants lost 20% or more. Results vary based on diet, exercise, dose tolerance, and individual biology. Weight loss is best maintained with ongoing use of the medication combined with lifestyle changes.

Coverage for Wegovy varies widely. Some commercial insurance plans cover it for obesity; others don't. Medicare and many Medicaid plans historically haven't covered weight loss medications, though this is evolving. Prior authorization is almost always required and often requires documentation of BMI, failed prior weight loss attempts, and related health conditions. Our team will verify your benefits and assist with prior authorization.

Side effects are similar to Ozempic but may be more pronounced at the higher dose. The most common are nausea, vomiting, diarrhea, constipation, and stomach discomfort — especially during dose escalation. These typically improve over weeks. Serious but rare risks include pancreatitis, gallbladder disease, increased heart rate, and a theoretical thyroid tumor risk based on animal data. Your endocrinologist will review your complete health history before prescribing.

Weight regain is common when Wegovy is stopped — clinical studies show most patients regain a significant portion of weight within a year of discontinuation. Wegovy is considered a long-term medication for chronic weight management, similar to how blood pressure medication is taken long-term. Your endocrinologist will help you develop a sustainable plan that may include ongoing medication, lifestyle support, and periodic reassessment.

Wegovy is approved for weight management and can be used in patients with Type 2 diabetes. However, if your primary goal is blood sugar control, your endocrinologist may recommend Ozempic or Mounjaro instead, as these have diabetes-specific labeling and cardiovascular outcome data. If your primary goal is weight loss and you also have diabetes, Zepbound (tirzepatide) may offer the best of both worlds — ask your doctor.

Most patients notice reduced appetite and some weight loss within the first 4 weeks. Significant weight loss — 5–10% of body weight — typically occurs over the first 12–20 weeks as the dose is gradually escalated. Maximum weight loss is usually reached around 60–68 weeks of treatment. The dose escalation schedule (0.25 mg → 0.5 mg → 1.0 mg → 1.7 mg → 2.4 mg) takes approximately 16–20 weeks to complete.